AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05092984
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation.
Trial: NCT05345509
Drug: IVL3003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil Long-Acting Injection, once S.C Injection
Trial: NCT05345509
Drug: IVL3003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil Long-Acting Injection, once IM Injection
Trial: NCT05024799
Drug: Fentanyl, propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in this group will be administered with fentanyl and propofol
Trial: NCT05024799
Drug: fentanyl and dexmedetomindine
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients in this group will be administered with fentanyl and dexmedetomindine
Trial: NCT05560477
Drug: AM3101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable drug product.
Trial: NCT05560477
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL 0.9% normal saline
Trial: NCT00000961
Drug: Anti-HIV Immune Serum Globulin (Human)
RxNorm normalized name: immune globulin subcutaneous (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04858711
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
Trial: NCT05093335
Drug: [68Ga]-Pentixafor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of 3 -5 mCi of \[68Ga\]-Pentixafor will be injected in all participants.
Trial: NCT04930809
Drug: VER-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Trial: NCT00241995
Drug: Anticonvulsants
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06485219
Drug: 11.2 mg/m2 Purinostat Mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.
Trial: NCT06485219
Drug: 15 mg/m2 Purinostat Mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.
Trial: NCT05009992
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally (PO)
Trial: NCT05039190
Drug: HBM9161 Injection (680mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 Injection
Trial: NCT05039190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Injection
Trial: NCT06109467
Drug: 5-Fluorouracil + leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive 400 mg/m\^2 5-Fluorouracil (5FU)+ 400 mg/m\^2 leucovorin day 1 of each 2 week cycle; 5FU continuous infusions on days 1 and 2 of each 2 week cycle. (5FU + leucovorin may be eliminated from regimen per PI discretion)
Trial: NCT05488548
Drug: EP31670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
Trial: NCT05376566
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
Trial: NCT05321069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05818553
Drug: PRAX-562
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral or G-tube treatment.
Trial: NCT06235983
Drug: LY3537982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05147467
Drug: APG2575
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
Trial: NCT06456528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04401423
Drug: TXA127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg per day
Trial: NCT05552781
Drug: H002 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule, Capsule
Trial: NCT04401423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg per day
Trial: NCT05529056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ophthalmic solution
Trial: NCT04098666
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet identical to metformin, up to 4 tablets a day
Trial: NCT04677673
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day
Trial: NCT05162027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
Trial: NCT06061536
Drug: Lipovirtide 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
Trial: NCT06061536
Drug: Lipovirtide 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
Trial: NCT06061536
Drug: Lipovirtide 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
Trial: NCT05199662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching IV TNK
Trial: NCT06374667
Drug: Y-3 intravenous injection
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included will be given Y-3 intravenous injection for 7 consecutive days.
Trial: NCT06573970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
Trial: NCT05875519
Drug: Local anaesthesia with vasocontrictor (Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg
Trial: NCT06208384
Drug: Statin eye drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of topical atorvastatin eye 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
Trial: NCT06208384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
Trial: NCT06422884
Drug: ENV-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, dosed once a day
Trial: NCT04520139
Drug: N-Acetyl-Cysteine
RxNorm normalized name: Dendrimer N-acetyl-cysteine
DrugBank: Acetylcysteine zidrimer (DB16496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05140512
Drug: ZOLADEX® 3.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
Trial: NCT05576038
Drug: Freedom SimpleCap Powder
RxNorm normalized name: Freedom SimpleCap Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freedom SimpleCap Powder is a high functionality capsule and tablet excipient composite comprised of filler, glidant, disintegrant and lubricant (ingredients include: Microcrystalline Cellulose, Silicon Dioxide Colloidal, Sodium Starch Glycolate, Sodium Stearyl Fumarate). This capsule is dye, lactose and gluten free and will not interfere with the AhR pathway. Freedom SimpleCap Powder makes oral capsule formulation convenient, quick and simple Thus, this SimpleCap Powder will be an appropriate placebo comparator for this study.
Trial: NCT05537051
Drug: PM1021, PM8001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
Trial: NCT05656105
Drug: DPA-714 PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPA-714 PET/MRI
Trial: NCT06443502
Drug: Concomitant Antibiotic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.
Trial: NCT06264414
Drug: DTT106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral route
Trial: NCT06247657
Drug: BL0006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.
Trial: NCT06275763
Drug: Phase C: Eplerenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
Trial: NCT06275763
Drug: Phase C: Spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
Trial: NCT06275763
Drug: Phase B: Triplixam / Elestar HCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
Trial: NCT05445843
Drug: JDQ443
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JDQ443 orally administered
Trial: NCT06153602
Drug: Acetaminophen 500Mg Tab
RxNorm normalized name: ACETAMINOPHEN 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab oral prn for postoperative pain score 1-3 q 6 h
Trial: NCT05070260
Drug: Intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Trial: NCT02006173
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00106548
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25mg/week
Trial: NCT06051240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White round tablet, 10 mm. Identical to experimental drug (lithium)
Trial: NCT06466538
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intracanal medicament
Trial: NCT06466538
Drug: Leddermix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leddermix
Trial: NCT06466538
Drug: Boswellia
RxNorm normalized name: boswellia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia
Trial: NCT04944654
Drug: BIKTARVY 50Mg-200Mg-25Mg Tablet
RxNorm normalized name: Biktarvy 50mg-200mg-25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
Trial: NCT05161611
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg of oral zinc sulfate will be given to neonates per day
Trial: NCT05970185
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
Trial: NCT05529849
Drug: TCMCB07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of TCMCB07
Trial: NCT05529849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching subcutaneous placebo
Trial: NCT06346184
Drug: RLD2302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 1 tablet once per period
Trial: NCT06346184
Drug: RLD2102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 1 tablet once per period
Trial: NCT05862701
Drug: Sulphur
RxNorm normalized name: Sulphur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Sulfur ointment
Trial: NCT03932656
Drug: Psychopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
Trial: NCT05584670
Drug: SAR445877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for solution for infusion
Trial: NCT05063500
Drug: polyene phosphatidylcholine capsules, 228mg/ particle.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
Trial: NCT05726851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2025 matched placebo IV infusion.
Trial: NCT05405868
Drug: Nicotinomide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide tablets (750mg)
Trial: NCT05405868
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06185829
Drug: Neurloeptanalgesic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual neuroleptanalgesic treatment
Trial: NCT04973982
Drug: Adoport
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
Trial: NCT05741437
Drug: CKD-378, QD, PO Drug: D745, D150, QD, PO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
Trial: NCT04898920
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
Trial: NCT03988231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
Trial: NCT04911881
Drug: IBI321
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
Trial: NCT05223660
Drug: Low dose Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 4 capsules, followed by multiple doses on Days 8-12
Trial: NCT05223660
Drug: High dose Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 6 capsules, followed by multiple doses on Days 8-12
Trial: NCT05916781
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare.
Trial: NCT05381142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered the same as Elinzanetant (BAY3427080)
Trial: NCT06372561
Drug: Melatonin (dressing material)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: melatonin powder 250mg (sigma, Aldrich)- white powder mixing with saline and applied on dental pulp
Trial: NCT06387186
Drug: Leucine-Enriched Essential Amino Acid powder
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.
Trial: NCT05561361
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
Trial: NCT05594472
Drug: Topical garamycin cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional topical treatment will be applied for 5 consecutive days on a comparable erosion
Trial: NCT00082251
Drug: Niacin extended release and simvastatin tablets
RxNorm normalized name: niacin / simvastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06218680
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
Trial: NCT05803200
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention was given as this is an observational study.
Trial: NCT06026748
Drug: XJ103 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XJ103 is a humanized monoclonal antibody.
Trial: NCT06026748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains only excipients.
Trial: NCT04857996
Drug: UBX1325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered a single 50 μL UBX1325 IVT injection
Trial: NCT05407909
Drug: SYHX2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHX2001 tablets, oral
Trial: NCT05007561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral sugar pill
Trial: NCT05046847
Drug: TQB3811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3811 is a second-generation TrkA inhibitor.
Trial: NCT05506176
Drug: SIM0417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose of 750 mg SIM0417 with 100 mg ritonavir.
Trial: NCT05506176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablet)
Trial: NCT05880056
Drug: Nerkardou (5 mg) & (10 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol oral dissolved film ODF(5 mg): equivalent to 5 mg of bisoprolol fumarate Bisoprolol oral dissolved film ODF (10 mg): equivalent to 10 mg of bisoprolol fumarate.
Trial: NCT05531422
Drug: Inhaled fentanyl aerosol
RxNorm normalized name: fentanyl Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Trial: NCT05531422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Trial: NCT04947254
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given ADT
Trial: NCT06022939
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT04856787
Drug: SHR-1701、 BP102 、XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2：Single Group~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
Trial: NCT04856787
Drug: SHR-1701、 BP102 、XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 3：Randomized~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
Trial: NCT06201897
Drug: ACTH/Oral Steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection ACTH or Oral Steroids in children with West Syndrome